Press release
Metastatic Pancreatic Cancer Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Panbela Therapeutics, SynerGene Therapeutics, and others
Metastatic Pancreatic Cancer Pipeline
In the Metastatic Pancreatic Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Pancreatic Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report
• DelveInsight's Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
• The leading Metastatic Pancreatic Cancer Companies includes Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
• Promising Metastatic Pancreatic Cancer Pipeline Therapies includes ACP-196, Galunisertib, Durvalumab, Gemcitabine, Albumin-bound paclitaxel, RX-3117, Olaratumab, Nab-paclitaxel, MM-398, Leucovorin, and others.
• The Metastatic Pancreatic Cancer Companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Pancreatic Cancer. The Metastatic Pancreatic Cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Pancreatic Cancer.
To explore more information on the latest breakthroughs in the Metastatic Pancreatic Cancer Pipeline treatment landscape of the report, click here @ Metastatic Pancreatic Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Pancreatic Cancer Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%.
Metastatic Pancreatic Cancer Emerging Drugs Profile
• Motixafortide: BioLineRx
• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
• HP518: Hinova Pharmaceuticals
For further information, refer to the detailed Metastatic Pancreatic Cancer Unmet Needs, Metastatic Pancreatic Cancer Market Drivers, and Market Barriers, click here for Metastatic Pancreatic Cancer Ongoing Clinical Trial Analysis - https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Pancreatic Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies Metastatic Pancreatic Cancer. The companies which have their Metastatic Pancreatic Cancer drug candidates in the most advanced stage, i.e phase III include Eleison Pharmaceuticals
Metastatic Pancreatic Cancer Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request a sample and discover the recent advances in Metastatic Pancreatic Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Pancreatic Cancer Treatment Landscape - https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Metastatic Pancreatic Cancer Pipeline Insight Report
• Coverage- Global
• Metastatic Pancreatic Cancer Companies- Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
• Metastatic Pancreatic Cancer Pipeline Therapies- ACP-196, Galunisertib, Durvalumab, Gemcitabine, Albumin-bound paclitaxel, RX-3117, Olaratumab, Nab-paclitaxel, MM-398, Leucovorin, and others
• Metastatic Pancreatic Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Metastatic Pancreatic Cancer Market Drivers and Metastatic Pancreatic Cancer Market Barriers, click here @ Metastatic Pancreatic Cancer Unmet Needs and Analyst Views - https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Pancreatic Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Eleison Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MDB 401 B: Panbela Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SBP 101: Takeda Oncology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Pancreatic Cancer Key Companies
21. Metastatic Pancreatic Cancer Key Products
22. Metastatic Pancreatic Cancer- Unmet Needs
23. Metastatic Pancreatic Cancer- Market Drivers and Barriers
24. Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
25. Metastatic Pancreatic Cancer Analyst Views
26. Metastatic Pancreatic Cancer Key Companies
27. Appendix
Got Queries? Find out the related information on Metastatic Pancreatic Cancer Mergers and acquisitions, Metastatic Pancreatic Cancer licensing activities @ Metastatic Pancreatic Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Pancreatic Cancer Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Panbela Therapeutics, SynerGene Therapeutics, and others here
News-ID: 3102356 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Pancreatic
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…
